Peptide Library/Performance & Body Composition/ITPP

ITPP

Research ChemicalModerate Research

Also known as: Myo-Inositol Trispyrophosphate · OXY111A

A synthetic allosteric effector of hemoglobin that enhances oxygen delivery to tissues, improving endurance, recovery, and potentially combating tumor hypoxia.

Overview

ITPP (Myo-Inositol Trispyrophosphate) is a synthetic molecule that acts as an allosteric effector of hemoglobin, modifying its oxygen-binding properties to enhance oxygen release to tissues. ITPP enters red blood cells and binds to hemoglobin, shifting the oxygen-hemoglobin dissociation curve to the right, which means hemoglobin releases oxygen more readily in peripheral tissues. This effectively increases tissue oxygenation without increasing red blood cell count or blood viscosity — a critical advantage over EPO. Enhanced tissue oxygenation improves aerobic capacity, endurance performance, recovery between efforts, and may have therapeutic applications in treating ischemic conditions and combating tumor hypoxia.

ITPP has attracted attention in both the performance enhancement and oncology research communities.

Mechanism of Action

Enters red blood cells via Band 3 anion transporter. Binds to the central cavity of deoxyhemoglobin, stabilizing the T-state (tense, low oxygen affinity) and shifting the oxygen-hemoglobin dissociation curve rightward. This increases P50 (the partial pressure at which hemoglobin is 50% saturated), enhancing oxygen unloading in peripheral tissues.

Key Benefits

Enhanced oxygen delivery to tissues

Improved endurance and aerobic capacity

Better recovery between training sessions

No increase in blood viscosity (unlike EPO)

Potential anti-tumor effects via hypoxia reduction

Improved tissue healing

Potential Side Effects

Injection site reactions

Mild headache

Potential GI discomfort

Limited long-term human safety data

Common Stacks

This peptide is commonly combined with the following compounds for synergistic effects:

AICARCardarine (GW-501516)L-CarnitineCoQ10 (Injectable)

Known Interactions

The following interactions have been documented for ITPP. Always consult a healthcare professional before combining compounds.

Synergistic (1)

Cardarine (GW-501516)Synergistic

ITPP enhances oxygen delivery to tissues while Cardarine improves fat oxidation and endurance. Together they boost both oxygen utilization and metabolic efficiency.

View all compound interactions

Scientific References

ITPP, a Novel Allosteric Effector of Hemoglobin, Enhances Oxygen Delivery and Reduces Tumor Hypoxia

Fylaktakidou KC, Lehn JM, Greferath R, Nicolau C

Proceedings of the National Academy of Sciences (2005)

Myo-Inositol Trispyrophosphate Treatment Leads to Anti-Angiogenic Effects in Tumors

Sihn G, Walter T, Klein JC, et al.

PLoS ONE (2007)

Quick Reference

Typical Dose

500mg-2000mg

Frequency

1x daily AM

Route

Subcutaneous or intravenous injection

Half-Life

~6-8 hours in RBCs

Cycle Length

4-12 weeks; 5 on 2 off or daily, followed by 2-4 weeks recovery

FDA Status

Research compound — not FDA approved. Has been studied in oncology clinical trials (OXY111A).

Need to calculate dosing?

Use our reconstitution calculator to determine exact syringe measurements.

Open Calculator

This information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.

Related Peptides in Performance & Body Composition

AICAR

An AMPK activator known as an 'exercise mimetic' that triggers the same metabolic pathways as endurance exercise, enhancing fat oxidation and glucose uptake.

Cardarine (GW-501516)

A PPARdelta agonist that dramatically enhances endurance, fat oxidation, and metabolic efficiency by reprogramming muscle fibers to preferentially burn fat.

Follistatin 344

A naturally occurring glycoprotein that inhibits myostatin and activin, removing the genetic brake on muscle growth and enabling enhanced muscle development.